NSAIDS inhibit the IL-1 β-induced IL-6 release from human post-mortem astrocytes: The involvement of prostaglandin E2

Brain Research

Volumn 777, Issue 1-2, 1997, Pages 210-218

  Blom, Michaela A A ^a,b,e   Van Twillert, Margriete G H ^b   De Vries, Sabine C ^b   Engels, F ^c   Finch, Caleb E ^d   Veerhuis, Robert ^a,b   Eikelenboom, Piet ^a  

^a Department of Psychiatry   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Alzheimer's disease; Human astrocytes; Interleukin 6; Interleukin 1 ; Prostaglandin E2

Indexed keywords

4 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 2 METHYL 1,2 OXAZIN 3 ONE; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CADAVER; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUROPROTECTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTROCYTES; ASTROCYTOMA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DEXAMETHASONE; DINOPROSTONE; HUMANS; INDOMETHACIN; INTERLEUKIN-1; INTERLEUKIN-6; ISOENZYMES; MEMBRANE PROTEINS; OXAZINES; PEROXIDASES; PHENOLS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TUMOR CELLS, CULTURED;

EID: 0031589751     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01204-3     Document Type: Article

References (58)

1. [1] K. Andersen, L.J. Launer, A. Ott, A.W. Hoes, M.M. Breteler, A. Hofman, Do non-steroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study, Neurology 45 (1995) 1441-1445.
2. [2] J.C.S. Breitner, B.A. Gau, K.A. Welsh, B.L. Plassman, W.M. McDonald, M.J. Helms, J.C. Anthony, Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a control co-twin study, Neurology 44 (1994) 227-232.
3. [3] M.L. Jenkinson, M.R. Bliss, A.T. Brain, D.L. Scott, Rheumatoid arthritis and senile dementia of Alzheimer's type, Br. J. Rheumatol. 28 (1989) 86-88.
4. [4] J. Rogers, L.C. Kirby, S.R. Hempelman, D.L. Berry, P.L. McGeer, A.W. Kaznaik, J. Zalinsky, M. Cofield, L. Mansukhani, P. Willson, F. Kogan, Clinical trial of indomethacin in Alzheimer's disease, Neurology 43 (1993) 1609-1613.
5. [5] W.F. Stewart, C. Kawas, M. Corrada, E.F. Metter, Risk of Alzheimer's disease and duration of NSAID use, Neurology 48 (1997) 626-632.
6. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease, Cell 52 (1988) 487-501.
7. 2-macroglobulin indicate an acute phase state in Alzheimer's disease cortices, FEBS Lett. 285 (1991) 111-114.
8. [8] P. Eikelenboom, F.C. Stam, Immunoglobulins and complement factors in senile plaques, Acta Neuropathol. (Berl) 57 (1982) 239-242.
9. 1-antichymotrypsin in cerebral β/A4 deposits in Alzheimer's disease, Res. Immunol. 143 (1992) 617-620.
10. [10] W.S.T. Griffin, J.G. Sheng, W.G. Roberts, R.E. Mrak, Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution, J. Neuropathol. Exp. Neurol. 54 (1995) 276-281.
11. [11] M. Huell, S. Strauss, B. Volk, M. Berger, J. Bauer, Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients, Acta Neuropathol. 89 (1995) 544-551.
12. [12] J.M. Rozemuller, P. Van der Valk, P. Eikelenboom, Activated microglia and cerebral amyloid deposits in Alzheimer's disease, Res. Immunol. 143 (1992) 646-649.
13. [13] D.G. Walker, S.U. Kim, P.L. McGeer, Complement and cytokine gene expression in cultured microglia derived from post-mortem human brains, J. Neurosci. Res. 40 (1995) 478-493.
14. [14] M.A.A. Blom, F.L. Van Muiswinkel, P. Eikelenboom, Mechanisms of inflammation in Alzheimer's disease, An. Psychiatry 6 (1996) 1-12.
15. [15] J.D. Buxbaum, M. Oishi, H.I. Chen, R. Pinkas-Kramarski, A.E. Jaffe, S.E. Gandy, P. Greencard, Cholinergic agonists and interleukin-1 regulate processing and secretion of the β/A4 amyloid protein precursor, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10075-10078.
16. [16] R. Del Bo, N. Angeretti, E. Lucca, M.G. De Simoni, G. Forloni, Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures, Neurosci. Lett. 188 (1995) 70-74.
17. [17] P. Eikelenboom, S.S. Zhan, W.A. Van Gool, D. Allsop, Inflammatory mechanisms in Alzheimer's disease, Trends Pharmacol. Sci. 15 (1994) 447-450.
18. [18] B.C. Gitter, L.M. Cox, R.E. Rydel, P.C. May, Amyloid β peptide potentiates cytokine secretion by interleukin-1 β-activated human astrocytoma cells, Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 10738-10741.
19. [19] D. Goldgaber, H.W. Harris, T. Hla, T. Maciag, R.J. Donnelly, J.S. Jacobson, M.P. Vitek, D.C. Gajdusek, Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells, Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 7606-7610.
20. [20] D. Guilian, J. Woodward, D.G. Young, J.F. Krebs, L.B. Lachman, Interleukin-1 injected in mammalian brain stimulates astrogliosis and neurovascularization, J. Neurosci. 8 (1988) 2485-2490.
21. [21] P. Vandenabeele, W. Fiers, Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated 'acute phase response' in the brain?, Immunol. Today 12 (1991) 217-219.
22. [22] F.L. Van Muiswinkel, R. Veerhuis, P. Eikelenboom, Amyloid β protein (Aβ) primes cultured rat microglial cells for an enhanced phorbol-myristate-acetate induced respiratory burst activity, J. Neurochem. 66 (1996) 2468-2476.
23. [23] P.S. Aisen, K.L. Davis, Inflammatory mechanisms in Alzheimer's disease: implications for therapy, Am. J. Psychiatry 151 (1994) 1105-1113.
24. [24] J.C.S. Breitner, New epidemiologic strategies in Alzheimer's disease may provide clues to prevention and cause, Neurobiol. Aging 150 (1994) S175-S177.
25. [25] J.C.S. Breitner, The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease, Annu. Rev. Med. 47 (1996) 401-411.
26. [26] M. Hüll, B.L. Fiebich, K. Lieb, S. Strauss, M. Berger, B. Volk, J. Bauer, Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options, Neurobiol. Aging 17 (1996) 795-800.
27. [27] P.L. McGeer, E. McGeer, J. Rogers, J. Sibley, Anti-inflammatory drugs and Alzheimer's disease, Lancet 335 (1990) 1037.
28. [28] P.L. McGeer, E.G. McGeer, The inflammatory response system of brain: implications for therapy of Alzheimer's disease and other neurodegenerative diseases, Brain Res. Rev. 21 (1995) 195-218.
29. [29] F.L. Van Muiswinkel, P. Eikelenboom, Do non-steroidal anti-inflammatory drugs (NSAID's) have a protective effect against dementia?, Drugs and Aging 9 (1996) 1-7.
30. [30] P. Dash, A.N. Moore, Enhanced processing of APP induced by IL-1β can be reduced by indomethacin and nordihydroguaiaretic acid, B.B.R.C. 208 (1995) 542-548.
31. [31] M.O. Fagarasan, P.S. Aisen, IL-1 and anti-inflammatory drugs modulate Aβ cytotoxicity in PC12 cells, Brain Res. 723 (1996) 231-234.
32. [32] T. Nishida, S. Nakai, T. Kawakami, K. Aihara, N. Nishino, Y. Hirai, Dexamethasone regulation of the expression of cytokine mRNAs induced by interleukin-1 in the astrocytoma cell line U373MG, FEBS Lett. 243 (1989) 25-29.
33. [33] I.L. Campbell, C.R. Abraham, E. Masliah, P. Kemper, J.D. Inglis, M.B.A. Oldstone, L. Mucke, Neurologic disease induced in transgenic mice cerebral overexpression of interleukin 6, Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 10061-10065.
34. [34] F. Aloisi, A. Carè, G. Borsellino, P. Gallo, S. Rosa, A. Bassani, A. Cabibbo, U. Testa, G. Levi, C. Peschle, Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1β and tumor necrosis factor-α, J. Immunol. 149 (1992) 2358-2366.
35. + astrocytes with neurofibrillary tangle stages, J. Neuropathol. Exp. Neurol. 56 (1997) 285-290.
36. [36] R. Brattsand, M. Linden, Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies, Alim. Pharm. Therap. 10 (1996) S81-S92.
37. [37] Haynes, R.C. Jr., ACTH; adrenocortical steroids; inhibitors of synthesis, in: A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds.), Goodman and Gilman's The pharmacological basis of therapeutics, 8th edn., New York, Pergamon Press, 1990.
38. [38] J.C. Frölich, A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes, Trends Pharmacol. Sci. 8 (1997) 30-34.
39. [39] E.T. Dayton, E.O. Major, Recombinant human interleukin 1β induces production of prostaglandins in primary human fetal astrocytes and immortalized human fetal astrocyte cultures, J. Neuroimmunol. 71 (1996) 11-18.
40. 2 induces interleukin-6 synthesis in human astroglioma cells, J. Neurochem. 68 (1997) 704-709.
41. [41] J.A. Mitchell, P. Akarasereenont, C. Thiemermann, R.J. Flower, J.R. Vane, Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase, Proc. Natl. Acad. Sci. U.S.A. 90 (1994) 11693-11697.
42. [42] M.K. O'Banion, J.C. Miller, J.W. Chang, M.D. Kaplan, P.D. Coleman, Interleukin-1β induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures, J. Neurochem. 66 (1996) 2532-2540.
43. [43] K. Siebert, J. Masferrer, Y. Zhang, S. Gregory, G. Olson, S. Hauser, K. Leahy, W. Perkins, P. Isakson, Mediation of inflammation by cyclooxygenase-2, Agents and actions 46 (1995) 41-50.
44. [44] A.M. Bendele, D.N. Benslay, J.T. Hom, S.M. Speathe, K.J. Ruterbories, T.D. Lindstrom, S.J. Lee, R.W. Naismith, Anti-inflammatory activity of BF389, a di-T-butylphenol, in animal models of arthritis, J. Pharmac. Exp. Therap. 260 (1992) 300-305.
45. [45] C.J.A. De Groot, C.H. Langeveld, C.A.M. Jongenelen, E.J. Montagne, P. Van de Valk, C.D. Dijkstra, Establishment of human adult astrocyte cultures derived from postmortem multiple sclerosis and control brain and spinal cord regions: immunophenotypical and functional characterization, J. Neurosci. Res. 49 (1997) 342-354.
46. [46] P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren., H. Bokesh, S. Kenney, M.R. Boyd, New colorimetric cytotoxicity assay for anti-cancer-drug screening, J. Natl. Cancer Inst. 82 (1990) 1107-1112.
47. [47] C. Weber, J.R. Beetens, R. Van der Wiele, M. Höller, F. De Clerck, Production of thromboxane and prostaglandins in human blood in the of thromboxane synthase inhibitors: a comparison of RIA and GC/MS determinations, Blood Coagulat. Fibrinol. 2 (1991) 7-15.
48. 2 potentiates interleukin-1β induced IL-6 production by human gingival fibroblasts, J. Clin. Perioden. 7 (1996) 635-640.
49. 2 in a murine model of inflammation: possible role of cycloogenase-2, Proc. Natl. Acad. Sci. U.S.A. 14 (1996) 4885-4890.
50. [50] J.L. Masferrer, B.S. Zweifel, P.T. Manning, S.D. Hauser, K.M. Leahy, W.G. Smith, P.C. Isakson, K. Siebert, Selective inhibition of inducable cyclooxygenase 2 in vivo is antiinflammatory and non ulcerogenic, Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3228-3232.
51. [51] J.R. Vane, Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs, Nature 231 (1971) 232-235.
52. 2 and lipocortin-1 in the CNS during the incubation period of murine scrapie correlates with progressive PrP accumulations, Brain Res. 754 (1997) 171-180.
53. [53] J.W. Chang, P.D. Coleman, M.K. O'Banion, Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease, Neurobiol. Aging 17 (1996) 801-808.
54. [54] P.T.-H. Wong, P.L. McGeer, E.G. McGeer, Decreased prostaglandin synthesis in postmortem cerebral cortex from patients with Alzheimer's disease, Neurochem. Int. 21 (1992) 197-202.
55. [55] R.I. Scheinman, P.C. Cogswell, A.K. Lofquist, A.S. Baldwin Jr., Role of transcriptional activation of I kappa B alpha in mediation immunosuppression by glucocorticoids, Science 270 (1995) 283-286.
56. [56] S.M. Sparacio, Y. Zhang, J. Vilcek, E.N. Benveniste, Cytokine regulation of interleukin-6 gene expression in astrocytes involves activation of an NF-kB-like nuclear protein, J. Neurochem. 39 (1992) 231-242.
57. [57] D.A. Kujubu, B.S. Fletcher, B.C. Varnum, R.W. Lim, H.R. Herschman, TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue, J. Biol. Chem. 266 (1991) 12866-12872.
58. [58] A. Ray, K.E. Prefontaine, Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor, Proc. Nat. Acad. Sci. U.S.A. 91 (1994) 752-756.